BioWorld

Feb. 7, 2006

QuatRx Files $86M IPO To Push Clinical Development

A month after starting its first Phase III trial, QuatRx Pharmaceuticals Co. filed for its initial public offering, hoping to raise $86.25 million. (BioWorld Today) Read More

Biotech Deals: Focusing On Pharma Relationships

ReNeuron's Results Positive As Stem Cell Meeting Starts

Bush's Proposed Budget Boosts FDA Funds In '07

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...